NCT01439152 (Clinical Trial/ BAY94-9343)

Study Title
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors (NCT01439152)

Trial Description
BAY94-9343 is an antibody-drug conjugate (ADC) directed against the cancer antigen mesothelin on tumor cells. This study will attempt to answer the following questions:
-What are the side effects of BAY94-9343 when given at different dose levels and schedules?
-What dose level and schedule of BAY94-9343 should be tested in future clinical research studies?
-How much BAY94-9343 is in the blood at specific times after  administration?
-Does the treatment with BAY94-9343 show any effect on the tumor growth?
-Are there specific biomarkers that might be able to explain why some patients respond to treatment and others do not?

This trial is sponsored by Bayer. [1]

Study Data

  • Condition: Solid Tumors
  • Interventions:
    • Drugs used in this trial
      • BAY94-9343
  • Phase: I
  • Estimated Enrollment: 141
  • Start: September 2011
  • Estimated Completion: December 2015
  • Last verified: June 2015

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: September 3, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.